RxDoctor Payments Data

Alyson Hall, MD

Ophthalmology · Bowie, MDNPI 1417973314

Payments from drug & device makers

$26,663in general payments, 2019–2025

Across 128 payments — averaging $208.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$18K
  • NEW World Medical,inc.$7K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$544
  • Glaukos Corporation$360
  • Alcon$312
  • Sight Sciences, Inc.$270
  • plus $572 from 9 others

What the payments were for

  • Consulting fees$5,35020%
  • Speaking & faculty fees$15,05056%
  • Travel & lodging$1,2265%
  • Food & beverage$4,85918%
  • Education$1130%
  • Gifts$640%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$26,663 in reported general payments places this provider in the 85th percentile of 493 ophthalmology providers in Maryland.

See all ophthalmology providers in Maryland

Medicare billing

Part B allowed, 2024
$735,973
Medicare patients
1,496
Services billed
4,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost259$156,456
CombiganBrimonidine Tartrate/Timolol265$136,904
RhopressaNetarsudil Mesylate132$88,431
RestasisCyclosporine51$67,359
VyzultaLatanoprostene Bunod86$50,524
RocklatanNetarsudil Mesylat/Latanoprost61$49,855
Alphagan PBrimonidine Tartrate71$38,535
Prednisolone Acetate423$31,862
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol141$29,488
Travoprost97$18,801
Brimonidine Tartrate294$17,463
Brinzolamide65$16,179
Travatan ZTravoprost18$15,652
Timolol MaleateTimolol Maleate/Pf50$14,026
SimbrinzaBrinzolamide/Brimonidine Tart40$13,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$17,658$399,254646 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$200$138,286193 claims
Bausch & Lomb Americas Inc.Vyzulta$157$50,52486 claims
AlconSimbrinza, Azopt$312$23,30655 claims
NovartisTravatan Z$70$15,65218 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$544$2,68915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 493 ophthalmology providers in Maryland.

Other ophthalmology in Bowie

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →